Funding Approved to Further Metabolomics Research
News Oct 23, 2017 | Original Story from the National Institutes of Health.
The NIH Common Fund’s Metabolomics program aims to increase national capacity in metabolomics by supporting the development of next generation technologies to enhance the sensitivity and speed with which specific elements of the cellular metabolome can be identified and quantified, providing training and mentoring opportunities, increasing the inventory of chemically identifiable metabolites through the synthesis and availability of high quality reference standards, and by promoting data sharing and collaboration.
Metabolomics has been approved for stage II funding
The NIH Common Fund Metabolomics Program has been approved for a second stage of support from fiscal years 2018-2021. In the second stage of the program, Common Fund will continue to support the development of resources that catalyze the effective use of metabolomics in basic and translational biomedical research. Investments in the second phase will focus on establishing a robust national repository for metabolomics data with the goal of making all NIH-supported metabolomics data publicly accessible and available for reuse; developing new computational tools to facilitate the analysis and interpretation of complex metabolomics data sets; and supporting projects to expedite unknown metabolite identification.
This article has been republished from materials provided by the National Institutes of Health. Note: material may have been edited for length and content. For further information, please contact the cited source.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE